Login to Your Account



BioCryst Reports Lead Flu Drug Fails In Phase III Against Placebo

By Kim Coghill


Wednesday, June 26, 2002
BioCryst Pharmaceuticals Inc. stopped development of its lead drug candidate, peramivir, on poor preliminary data from a Phase III influenza study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription